Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | SARS-CoV-2 | Research

Resurgence of SARS-CoV-2 Delta after Omicron variant superinfection in an immunocompromised pediatric patient

Authors: Arghavan Alisoltani, Lacy M. Simons, Maria Francesca Reyes Agnes, Taylor A. Heald-Sargent, William J. Muller, Larry K. Kociolek, Judd F. Hultquist, Ramon Lorenzo-Redondo, Egon A. Ozer

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Background

Persistent SARS-CoV-2 infection in immunocompromised hosts is thought to contribute to viral evolution by facilitating long-term natural selection and viral recombination in cases of viral co-infection or superinfection. However, there are limited data on the longitudinal intra-host population dynamics of SARS-CoV-2 co-infection/superinfection, especially in pediatric populations. Here, we report a case of Delta-Omicron superinfection in a hospitalized, immunocompromised pediatric patient.

Methods

We conducted Illumina whole genome sequencing (WGS) for longitudinal specimens to investigate intra-host dynamics of SARS-CoV-2 strains. Topoisomerase PCR cloning of Spike open-reading frame and Sanger sequencing of samples was performed for four specimens to validate the findings. Analysis of publicly available SARS-CoV-2 sequence data was performed to investigate the co-circulation and persistence of SARS-CoV-2 variants.

Results

Results of WGS indicate the patient was initially infected with the SARS-CoV-2 Delta variant before developing a SARS-CoV-2 Omicron variant superinfection, which became predominant. Shortly thereafter, viral loads decreased below the level of detection before resurgence of the original Delta variant with no residual trace of Omicron. After 54 days of persistent infection, the patient tested negative for SARS-CoV-2 but ultimately succumbed to a COVID-19-related death. Despite protracted treatment with remdesivir, no antiviral resistance mutations emerged. These results indicate a unique case of persistent SARS-CoV-2 infection with the Delta variant interposed by a transient superinfection with the Omicron variant. Analysis of publicly available sequence data suggests the persistence and ongoing evolution of Delta subvariants despite the global predominance of Omicron, potentially indicative of continued transmission in an unknown population or niche.

Conclusion

A better understanding of SARS-CoV-2 intra-host population dynamics, persistence, and evolution during co-infections and/or superinfections will be required to continue optimizing patient care and to better predict the emergence of new variants of concern.
Appendix
Available only for authorised users
Literature
2.
go back to reference Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. The Lancet. 2021;398(10317):2126–8.CrossRef Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. The Lancet. 2021;398(10317):2126–8.CrossRef
7.
go back to reference Cherian S et al. “SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India,“ Microorganisms, vol. 9, no. 7, p. 1542, 2021. Cherian S et al. “SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India,“ Microorganisms, vol. 9, no. 7, p. 1542, 2021.
8.
go back to reference Wang Y, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine. 2021;40:101129.CrossRefPubMedPubMedCentral Wang Y, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine. 2021;40:101129.CrossRefPubMedPubMedCentral
9.
go back to reference Grant R, et al. Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: results from a nationwide case-control study in France. Lancet Reg Health-Europe. 2022;13:100278.CrossRef Grant R, et al. Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: results from a nationwide case-control study in France. Lancet Reg Health-Europe. 2022;13:100278.CrossRef
10.
go back to reference Nyberg T, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study. The Lancet. 2022;399(10332):1303–12.CrossRef Nyberg T, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study. The Lancet. 2022;399(10332):1303–12.CrossRef
11.
12.
go back to reference Veneti L et al. “Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA. 1 variant compared with the Delta variant, Norway, December 2021 to January 2022,“ Eurosurveillance, vol. 27, no. 4, p. 2200077, 2022. Veneti L et al. “Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA. 1 variant compared with the Delta variant, Norway, December 2021 to January 2022,“ Eurosurveillance, vol. 27, no. 4, p. 2200077, 2022.
13.
go back to reference Dezordi FZ et al. Unusual SARS-CoV-2 intrahost diversity reveals lineage superinfection, Microb Genomics, vol. 8, no. 3, 2022. Dezordi FZ et al. Unusual SARS-CoV-2 intrahost diversity reveals lineage superinfection, Microb Genomics, vol. 8, no. 3, 2022.
15.
go back to reference Combes P, et al. Evidence of co-infections during Delta and Omicron SARS-CoV-2 variants co-circulation through prospective screening and sequencing. Clin Microbiol Infect. 2022;28(11):1503. e5-1503. e8.CrossRefPubMedCentral Combes P, et al. Evidence of co-infections during Delta and Omicron SARS-CoV-2 variants co-circulation through prospective screening and sequencing. Clin Microbiol Infect. 2022;28(11):1503. e5-1503. e8.CrossRefPubMedCentral
16.
go back to reference Zayet S, Vuillemenot J-B, Josset L, Gendrin V, Klopfenstein T. Simultaneous co-infection with Omicron (B. 1.1. 529) and Delta (21A/478K. V1) SARS-CoV-2 variants confirmed by whole genome sequencing. Int J Infect Dis. 2022;124:104–6.CrossRefPubMedPubMedCentral Zayet S, Vuillemenot J-B, Josset L, Gendrin V, Klopfenstein T. Simultaneous co-infection with Omicron (B. 1.1. 529) and Delta (21A/478K. V1) SARS-CoV-2 variants confirmed by whole genome sequencing. Int J Infect Dis. 2022;124:104–6.CrossRefPubMedPubMedCentral
17.
18.
go back to reference Wertheim JO, et al. Detection of SARS-CoV-2 intra-host recombination during superinfection with alpha and Epsilon variants in New York City. Nat Commun. 2022;13(1):3645.CrossRefPubMedPubMedCentral Wertheim JO, et al. Detection of SARS-CoV-2 intra-host recombination during superinfection with alpha and Epsilon variants in New York City. Nat Commun. 2022;13(1):3645.CrossRefPubMedPubMedCentral
19.
go back to reference Tarhini H, et al. Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection. J Infect Dis. 2021;223(9):1522–7.CrossRefPubMed Tarhini H, et al. Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection. J Infect Dis. 2021;223(9):1522–7.CrossRefPubMed
20.
go back to reference Pérez-Lago L, et al. SARS‐CoV‐2 superinfection and reinfection with three different strains. Transbound Emerg Dis. 2022;69(5):3084–9.CrossRefPubMed Pérez-Lago L, et al. SARS‐CoV‐2 superinfection and reinfection with three different strains. Transbound Emerg Dis. 2022;69(5):3084–9.CrossRefPubMed
22.
go back to reference Simons LM, et al. De novo emergence of SARS-CoV‐2 spike mutations in immunosuppressed patients. Transpl Infect Disease. 2022;24(6):e13914.CrossRef Simons LM, et al. De novo emergence of SARS-CoV‐2 spike mutations in immunosuppressed patients. Transpl Infect Disease. 2022;24(6):e13914.CrossRef
23.
go back to reference Weigang S, et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nat Commun. 2021;12(1):6405.CrossRefPubMedPubMedCentral Weigang S, et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nat Commun. 2021;12(1):6405.CrossRefPubMedPubMedCentral
24.
go back to reference Scherer EM, et al. SARS-CoV-2 evolution and immune escape in immunocompromised patients. N Engl J Med. 2022;386(25):2436–8.CrossRefPubMed Scherer EM, et al. SARS-CoV-2 evolution and immune escape in immunocompromised patients. N Engl J Med. 2022;386(25):2436–8.CrossRefPubMed
25.
go back to reference Ozer EA, et al. Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. Nat Commun. 2022;13(1):1–13.CrossRef Ozer EA, et al. Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. Nat Commun. 2022;13(1):1–13.CrossRef
27.
go back to reference Nguyen L-T, Schmidt HA, Von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol. 2015;32(1):268–74.CrossRefPubMed Nguyen L-T, Schmidt HA, Von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol. 2015;32(1):268–74.CrossRefPubMed
28.
go back to reference Kalyaanamoorthy S, Minh BQ, Wong TK, Von Haeseler A, Jermiin LS. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat Methods. 2017;14(6):587–9.CrossRefPubMedPubMedCentral Kalyaanamoorthy S, Minh BQ, Wong TK, Von Haeseler A, Jermiin LS. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat Methods. 2017;14(6):587–9.CrossRefPubMedPubMedCentral
29.
go back to reference Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0, Systematic biology, vol. 59, no. 3, pp. 307–21, 2010. Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0, Systematic biology, vol. 59, no. 3, pp. 307–21, 2010.
30.
go back to reference Hoang DT, Chernomor O, Von Haeseler A, Minh BQ, Vinh LS. UFBoot2: improving the ultrafast bootstrap approximation. Mol Biol Evol. 2018;35(2):518–22.CrossRefPubMed Hoang DT, Chernomor O, Von Haeseler A, Minh BQ, Vinh LS. UFBoot2: improving the ultrafast bootstrap approximation. Mol Biol Evol. 2018;35(2):518–22.CrossRefPubMed
31.
go back to reference Wickham H. ggplot2. Wiley Interdisciplinary Reviews: Computational Statistics. 2011;3(2):180–5.CrossRef Wickham H. ggplot2. Wiley Interdisciplinary Reviews: Computational Statistics. 2011;3(2):180–5.CrossRef
33.
go back to reference Sagulenko P, Puller V, Neher RA. “TreeTime: Maximum-likelihood phylodynamic analysis,“ Virus evolution, vol. 4, no. 1, p. vex042, 2018. Sagulenko P, Puller V, Neher RA. “TreeTime: Maximum-likelihood phylodynamic analysis,“ Virus evolution, vol. 4, no. 1, p. vex042, 2018.
35.
go back to reference Drummond AJ, Rambaut A, Shapiro B, Pybus OG. Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol. 2005;22(5):1185–92.CrossRefPubMed Drummond AJ, Rambaut A, Shapiro B, Pybus OG. Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol. 2005;22(5):1185–92.CrossRefPubMed
36.
go back to reference Tamura T, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun. 2023;14(1):2800.CrossRefPubMedPubMedCentral Tamura T, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun. 2023;14(1):2800.CrossRefPubMedPubMedCentral
37.
go back to reference Gandhi S, et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun. 2022;13(1):1547.CrossRefPubMedPubMedCentral Gandhi S, et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun. 2022;13(1):1547.CrossRefPubMedPubMedCentral
38.
go back to reference Hogan JI, et al. Remdesivir Resistance in Transplant recipients with Persistent Coronavirus Disease 2019. Clin Infect Dis. 2023;76(2):342–5.CrossRefPubMed Hogan JI, et al. Remdesivir Resistance in Transplant recipients with Persistent Coronavirus Disease 2019. Clin Infect Dis. 2023;76(2):342–5.CrossRefPubMed
39.
go back to reference Focosi D, Maggi F, McConnell S, Casadevall A. Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: a GISAID exploratory analysis. Antiviral Res. 2022;198:105247.CrossRefPubMedPubMedCentral Focosi D, Maggi F, McConnell S, Casadevall A. Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: a GISAID exploratory analysis. Antiviral Res. 2022;198:105247.CrossRefPubMedPubMedCentral
43.
go back to reference Sentis C et al. “SARS-CoV-2 Omicron variant, lineage BA. 1, is associated with lower viral load in nasopharyngeal samples compared to Delta variant,“ Viruses, vol. 14, no. 5, p. 919, 2022. Sentis C et al. “SARS-CoV-2 Omicron variant, lineage BA. 1, is associated with lower viral load in nasopharyngeal samples compared to Delta variant,“ Viruses, vol. 14, no. 5, p. 919, 2022.
44.
go back to reference Wolter N, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet. 2022;399(10323):437–46.CrossRef Wolter N, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet. 2022;399(10323):437–46.CrossRef
45.
go back to reference Twohig KA, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35–42.CrossRefPubMedPubMedCentral Twohig KA, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35–42.CrossRefPubMedPubMedCentral
46.
go back to reference Ong SWX et al. Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern: a retrospective cohort study comparing B. 1.1. 7 (alpha), B. 1.351 (Beta), and B. 1.617. 2 (Delta), Clin Infect Dis, vol. 75, no. 1, pp. e1128-e1136, 2022. Ong SWX et al. Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern: a retrospective cohort study comparing B. 1.1. 7 (alpha), B. 1.351 (Beta), and B. 1.617. 2 (Delta), Clin Infect Dis, vol. 75, no. 1, pp. e1128-e1136, 2022.
49.
go back to reference Rueca M et al. “Compartmentalized replication of SARS-Cov-2 in upper vs. lower respiratory tract assessed by whole genome quasispecies analysis,“ Microorganisms, vol. 8, no. 9, p. 1302, 2020. Rueca M et al. “Compartmentalized replication of SARS-Cov-2 in upper vs. lower respiratory tract assessed by whole genome quasispecies analysis,“ Microorganisms, vol. 8, no. 9, p. 1302, 2020.
50.
go back to reference Ke R, et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat Microbiol. 2022;7(5):640–52.CrossRefPubMedPubMedCentral Ke R, et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat Microbiol. 2022;7(5):640–52.CrossRefPubMedPubMedCentral
51.
go back to reference Jakwerth CA, et al. Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism. J Mol Med. 2022;100(4):613–27.CrossRefPubMed Jakwerth CA, et al. Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism. J Mol Med. 2022;100(4):613–27.CrossRefPubMed
53.
go back to reference Islam A, et al. Transmission dynamics and susceptibility patterns of SARS-CoV-2 in domestic, farmed and wild animals: sustainable one health surveillance for conservation and public health to prevent future epidemics and pandemics. Transbound Emerg Dis. Sep 2022;69(5):2523–43. https://doi.org/10.1111/tbed.14356. Islam A, et al. Transmission dynamics and susceptibility patterns of SARS-CoV-2 in domestic, farmed and wild animals: sustainable one health surveillance for conservation and public health to prevent future epidemics and pandemics. Transbound Emerg Dis. Sep 2022;69(5):2523–43. https://​doi.​org/​10.​1111/​tbed.​14356.
Metadata
Title
Resurgence of SARS-CoV-2 Delta after Omicron variant superinfection in an immunocompromised pediatric patient
Authors
Arghavan Alisoltani
Lacy M. Simons
Maria Francesca Reyes Agnes
Taylor A. Heald-Sargent
William J. Muller
Larry K. Kociolek
Judd F. Hultquist
Ramon Lorenzo-Redondo
Egon A. Ozer
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
SARS-CoV-2
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02186-w

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.